SAM
ZYME icon

Stenahm Asset Management’s Zymeworks ZYME Stock Holding History

Stenahm Asset Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$2.36M – 29
2020
Q4 		$2.36M Buy
+50,000
New +$2.32M 1.99% 17

Other funds holding ZYME

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Stenahm Asset Management's ZYME Position: Q1 2021 in Review

Stenahm Asset Management sold out of Zymeworks (ZYME) in Q1 2021, closing a stake of 50,000 shares — an estimated $2.36M sold.

Stenahm Asset Management first reported a position in ZYME in Q4 2020 and held it in 1 quarter. The position peaked at $2.36M in Q4 2020. 125 funds tracked by Wall St. Rank hold ZYME as of Q1 2021.

  • Stenahm Asset Management reported no remaining Zymeworks position as of Q1 2021 after selling out during the quarter.
  • Stenahm Asset Management sold 50,000 Zymeworks shares in Q1 2021, an estimated $2.36M.
  • Stenahm Asset Management first reported a position in Zymeworks in Q4 2020 and held it in 1 quarter.
  • Stenahm Asset Management's Zymeworks position peaked at $2.36M in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Zymeworks as of Q1 2021.

Based on Stenahm Asset Management's 13F filing for Q1 2021, filed 7 May 2021.